Autopsy report · NCT04765423

Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease

“Poor patient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Case Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Malignant Neoplasm of Prostate

Interventions

[F-18] NaF PET/CT; [F-18] fluciclovine PET/CT

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (93% match in meaning)
• Dose-adjusted EPOCH-R in MYC Positive DLBCL
  “Poor accrual of eligible patients” (89% match in meaning)
• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (89% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (81% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.